Update for Customers: Microsoft Remote Desktop Services Remote Code Execution Vulnerability
Abbott is aware of and actively monitoring updates related to the Remote Desktop Services Remote Code Execution vulnerability (CVE-2019-0708), which was announced by Microsoft on May 14, 2019.
At this time, we have received no reports of this vulnerability impacting the clinical use of any Abbott systems or products. Abbott product teams are evaluating this vulnerability to determine if there is any impact to products that utilize the affected Microsoft operating systems. Abbott is also evaluating operating system patches for potentially impacted products.
If there are any additional actions or recommendations related to individual Abbott products, customers will be notified through normal customer support processes.
Abbott is committed to ensuring the safety, security, integrity and regulatory compliance of our products. Customers with any product or site-specific concerns should contact their Abbott sales or service representative.
More background on the Remote Desktop Services Remote Code Execution vulnerability can be found here:
(Last updated: May 22, 2019)
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.